Evofem Biosciences
Amanda Waier, CPA, CMA, currently serves as the Director of SEC Reporting and Operational Accounting at Evofem Biosciences, a role assumed in July 2023. Previous experience includes Senior Director of Financial Reporting & Technical Accounting at Curaleaf, where Amanda managed complex financial statement filings, led the implementation of a stock-based compensation service provider, and conducted technical accounting analyses. Prior positions include Senior Financial Analyst and various roles at Weyerhaeuser, Applied Materials, and Deloitte, where responsibilities ranged from financial statement preparation and analysis to audits and internal controls. Amanda holds an MS in Accounting from UNLV Lee Business School, an MBA from Baker University, and a Bachelor’s degree in Psychology from The University of Kansas.
This person is not in any teams
This person is not in any offices
Evofem Biosciences
1 followers
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi®, is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company’s lead product candidate, EVO100, is being evaluated for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, ‘EVOGUARD.’